Abstract
Highlights of primary prevention of death in patients with ventricular arrhythmias (VA) are discussed. Overview of all main clinical trials exploring various anti-arrhythmic drugs in prevention of death in patients with VA is presented. It is emphasized that in patients with organic heart disease and VA only beta-blockers and amiodarone are able to reduce mortality, while other drugs have no effect on mortality, or they even increase mortality mainly due to arrhythmogenic effect. Recent clinical studies of the cardioverter-defibrillators efficacy in these patients are presented. It is shown that the use of cardioverter defibrillators compared with pharmacotherapy is more effective in prevention of fatal outcomes.
Highlights
Рассматриваются актуальные вопросы первичной профилактики смерти у больных с желудочковыми аритмиями (ЖА)
It is emphasized that in patients with organic heart disease and ventricular arrhythmias (VA) only beta-blockers and amiodarone are able to reduce mortality, while other drugs have no effect on mortality, or they even increase mortality mainly due to arrhythmogenic effect
It is shown that the use of cardioverter defibrillators compared with pharmacotherapy is more effective in prevention of fatal outcomes
Summary
Российская медицинская академия последипломного образования. 123995, Москва, ул. Баррикадная, д. 2/1. Возможности антиаритмической терапии в первичной профилактике смерти у больных с желудочковыми аритмиями Ю.А. Приведён обзор всех основных клинических исследований, посвящённых изучению возможностей различных антиаритмических препаратов в профилактике смерти у больных с ЖА. The possibilities of antiarrhythmic therapy in primary prevention of death in patients with ventricular arrhythmias Yu.A. Bunin* Russian Medical Academy of Postgraduate Education. Highlights of primary prevention of death in patients with ventricular arrhythmias (VA) are discussed. Overview of all main clinical trials exploring various anti-arrhythmic drugs in prevention of death in patients with VA is presented. По мнению экспертов АСС/АНА/ESC [1], при анализе исследований, посвященных данной проблеме (особенно у больных, перенесших инфаркт миокарда (ИМ) или с хронической сердечной недостаточностью (ХСН)), кроме внезапной сердечной смерти (ВСС) надежной конечной точкой является общая смертность. Сведения об авторе: Бунин Юрий Андреевич — д.м.н., профессор кафедры кардиологии РМАПО
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
